bjkim97
☆    

Korea / Seoul,
2018-05-30 08:41
(917 d 14:59 ago)

Posting: # 18828
Views: 1,663
 

 How to demonstrate the bioequivalence of sulodexide [Design Issues]

We are planning to development of the sulodexide.

As far as I Know, this product does not have accurate guldelines and design.

So I have reviewed several documents. The FDA and EMEA have identified guidelines for LMWH.

The sulodexide is defined as follows.

Sulodexide is highly purifuled mixture of glycosaminoglycans composed of FMH (Fast Moving Heparin) (80%) and Dermatan sulfate (20%).

I will refer to the FDA enoxaparin recommend guidelines for pharmacodynamic equivalence.

Just one question:
I am not sure if enoxaparin recommendations can be applied to Sulodexide.

I want to hear your opinion. Please give me your opinion

Thanks.

BJ
Activity
 Admin contact
21,232 posts in 4,427 threads, 1,481 registered users;
online 7 (2 registered, 5 guests [including 4 identified bots]).
Forum time: Wednesday 22:41 CET (Europe/Vienna)

A big data-analyst is an expert
in producing misleading conclusions from huge datasets.
It is much more efficient to use a statistician,
who can do the same with small ones.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5